NMD Pharma A/S has revealed that the initial patient has received their first dose in a Phase II clinical study of the ClC-1 inhibitor NMD670 in individuals affected by spinal muscular atrophy.

This article summarized the latest R&D progress of Magnesium Salicylate, the Mechanism of Action for Magnesium Salicylate, and the drug target R&D trends for Magnesium Salicylate.

The Renin-Angiotensin System (RAS) is a crucial fluid-regulating system composed of a series of peptide hormones and corresponding enzymes.

This article summarized the latest R&D progress of Miglitol, the Mechanism of Action for Miglitol, and the drug target R&D trends for Miglitol.

Sandoz gains consent from the European Commission for its unique multiple sclerosis biosimilar, Tyruko® (natalizumab) in Europe.

This article summarized the latest R&D progress of Nalidixic Acid, the Mechanism of Action for Nalidixic Acid, and the drug target R&D trends for Nalidixic Acid.

RANKL, or Receptor Activator of Nuclear Factor Kappa-B Ligand, is a crucial protein involved in the regulation of bone metabolism in the human body.

This article summarized the latest R&D progress of Naphazoline Hydrochloride, the Mechanism of Action for Naphazoline Hydrochloride, and the drug target R&D trends for Naphazoline Hydrochloride.

Lantern Pharma Inc. has started Phase 1 clinical trial on its experimental drug, LP-184, for advanced solid tumors. This is part of the company's ongoing clinical drug development.

This article summarized the latest R&D progress of Phenazepam, the Mechanism of Action for Phenazepam, and the drug target R&D trends for Phenazepam.

Pre-exposure prophylaxis (PrEP) is a preventive measure that involves the use of antiretroviral drugs to reduce the risk of HIV infection in individuals who are not infected but are at high risk of exposure.

This article summarized the latest R&D progress of Phendimetrazine Tartrate, the Mechanism of Action for Phendimetrazine Tartrate, and the drug target R&D trends for Phendimetrazine Tartrate.